Full Press Release Details
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
LTRN Positive Sentiment
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Key Takeaway: Lantern Pharma Inc. has successfully closed a registered direct offering, raising up to $8 million. This funding is expected to support the company's ongoing growth initiatives and enhance its operational capabilities. The announcement highlights the company's strategic financial moves in the biopharma sector.
Market Sentiment Analysis
POSITIVE FACTORS
- Lantern Pharma secures up to $8 million in funding.
- The offering supports the company's growth initiatives.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+20%
120-day peak, hindsight
Typical move
4%
average across 5 past catalysts
Cash runway
~6 mo
Medium dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxel
Phase 3 · Non-small Cell Lung Cancer
Frequently Asked Questions
What is the amount raised by Lantern Pharma?
Lantern Pharma raised up to $8 million through a registered direct offering.
What will the funding support?
The funding will support Lantern Pharma's growth initiatives.